Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0001104659-25-061185·CASI Pharmaceuticals, Inc.
Schedule 13D ownership disclosure
CASI PHARMACEUTICALS INC
Ordinary Shares · CUSIP: G1933S101
Event date: 2025-06-16
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- WEI-WU HE, Ph.D.Reported CIK 0001542073
Shares: 3,735,535.00 · Class: 23.8%
- HUIYING MEMORIAL FOUNDATION
Shares: 407,644.00 · Class: 2.6%
- EMERGING TECHNOLOGY PARTNERS, LLC
Shares: 1,097,341.00 · Class: 7.1%
- ETP Global Fund L.P.
Shares: 753,234.00 · Class: 4.9%
- ETP BIOHEALTH III FUND , L.P.
Shares: 300,000.00 · Class: 1.9%
- HE Family GRAT
Shares: 100,000.00 · Class: 0.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-061185
- Form type
- SCHEDULE 13D/A
- Filer
- CASI Pharmaceuticals, Inc.
- CIK
- CIK 1962738
- Filed
- Jun 20, 2025
- Reporting period
- Jun 16, 2025
- Description
- Schedule 13D beneficial ownership